AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia
December 3, 2018Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …
Novartis unveils strong longer-term Kymriah data at ASH 2018
December 3, 2018Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
Top Ten most popular articles on Pharmafile.com this week
November 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Immuno Biotech, NHS, Roche, autism, biosimilars, pharma, top ten
We’ve come to the end of November, and with only one month of the year left to go, the industry …
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
November 30, 2018Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …
MSD chalks up two HIV drug approvals in Europe
November 30, 2018Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma
MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …
83% in healthcare say UK will not be attractive for R&D and manufacturing post-Brexit
November 30, 2018Medical Communications, Research and Development R&D, UK, brexit, pharma
As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK …
Bayer announces major restructure, 12,000 jobs to go
November 30, 2018Medical Communications, Sales and Marketing Bayer, job cuts, monsanto, pharma
Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its …
UK is among the first to meet UN targets for HIV treatment and prevention, Public Health England says
November 29, 2018Medical Communications HIV, UK, pharma
The UK is among the first countries in the world to meet the HIV treatment targets set out by the …
Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia
November 29, 2018Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia
Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion
November 29, 2018Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion
The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …
Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS
November 29, 2018Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma
Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …
NICE recommends Bayer’s Stivarga for advanced hepatocellular carcinoma
November 29, 2018Sales and Marketing Bayer, NICE, Stivarga, UK, pharma
The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on …
Roche’s Genentech to acquire inflammatory drug discovery firm Jecure
November 28, 2018Research and Development, Sales and Marketing Genentech, Jecure, Roche, liver disease, nash, pharma
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of …
UK cervical cancer screening rates fall to 21-year low
November 28, 2018Medical Communications, Research and Development Cancer, NHS, UK, cervical cancer, pharma
A report by NHS Digital has revealed that cervical cancer screening coverage has fallen to 71.4%, down from 72% in …
Teva’s EpiPen generic retails for same price as Mylan’s own
November 28, 2018Research and Development, Sales and Marketing Mylan, Teva, epipen, pharma
Israeli generics firm Teva has revealed the price tag of its generic version of Mylan’s EpiPen epinephrine auto-injector, and, at …
Bayer’s Jivi approved in Europe for previously treated haemophilia A
November 28, 2018Research and Development, Sales and Marketing Bayer, Jivi, haemophilia, pharma
Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from …
European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer
November 27, 2018Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma
Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …
Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz
November 27, 2018Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma
The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …
Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling
November 27, 2018Manufacturing and Production, Research and Development asthma, pharma, trial failure, vectura
Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, …
NHS to save £300 million by switching to Humira biosimilars
November 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
